QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:RLMD

Relmada Therapeutics (RLMD) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)
Free RLMD Stock Alerts
$4.00
-0.30 (-6.98%)
(As of 04:00 PM ET)
Compare
Today's Range
$3.95
▼
$4.31
50-Day Range
$4.30
▼
$6.80
52-Week Range
$2.36
▼
$7.22
Volume
152,611 shs
Average Volume
255,501 shs
Market Capitalization
$120.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Relmada Therapeutics MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
525.0% Upside
$25.00 Price Target
Short Interest
Bearish
5.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.45
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$350,305 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.53) to ($2.86) Per Share

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.67 out of 5 stars

Medical Sector

431st out of 911 stocks

Pharmaceutical Preparations Industry

191st out of 412 stocks

See Top Rated MarketRank™ Stocks Here
RLMD stock logo

About Relmada Therapeutics Stock (NASDAQ:RLMD)

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

RLMD Stock Price History

RLMD Stock News Headlines

April 16, 2024 | finance.yahoo.com
RELMADA THERAPEUT.DL-,001 (4E2.F)
March 21, 2024 | seekingalpha.com
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
April 19, 2024 | Crypto Swap Profits (Ad)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
March 21, 2024 | markets.businessinsider.com
Optimistic Buy Rating for Relmada Therapeutics Amidst Strong Phase 3 Trial Prospects and Financial Stability
March 20, 2024 | finance.yahoo.com
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript
March 20, 2024 | finanznachrichten.de
Relmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 20, 2024 | finance.yahoo.com
Q4 2023 Relmada Therapeutics Inc Earnings Call
March 19, 2024 | investorplace.com
RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023
April 19, 2024 | Crypto Swap Profits (Ad)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
March 19, 2024 | benzinga.com
Recap: Relmada Therapeutics Q4 Earnings
March 19, 2024 | finance.yahoo.com
Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results
March 19, 2024 | prnewswire.com
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 19, 2024 | msn.com
Options Volatility and Implied Earnings Moves Today, March 19, 2024
March 18, 2024 | msn.com
Relmada Therapeutics FY 2023 Earnings Preview
March 16, 2024 | finance.yahoo.com
RLMD Apr 2024 2.500 put
March 5, 2024 | prnewswire.com
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
February 13, 2024 | investing.com
Relmada Therapeutics Inc (RLMD)
February 5, 2024 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Immunocore Holdings (IMCR), Thermo Fisher (TMO)
February 4, 2024 | thestreet.com
Relmada Therapeutics Inc.
February 2, 2024 | msn.com
Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying
February 1, 2024 | marketwatch.com
Relmada Therapeutics Shares Hit 52-Week High After Execs Buy Shares
February 1, 2024 | finance.yahoo.com
Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares
January 30, 2024 | benzinga.com
Relmada Therapeutics Stock (NASDAQ:RLMD) Dividends: History, Yield and Dates
January 23, 2024 | morningstar.com
Relmada Therapeutics Inc RLMD
January 23, 2024 | finance.yahoo.com
Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) market cap touched US$109m last week, benefiting both individual investors who own 39% as well as institutions
January 4, 2024 | realmoney.thestreet.com
Mizuho sees weakness in Relmada Therapeutics shares as buying opportunity
January 4, 2024 | marketwatch.com
Relmada Therapeutics Shares Slide as Medical Chief Exits
See More Headlines
Receive RLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
4/19/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RLMD
CUSIP
N/A
CIK
1553643
Web
www.relmada.com
Phone
(786) 629-1376
Fax
N/A
Employees
20
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$25.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+481.4%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-98,790,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-93.44%
Return on Assets
-85.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.00
Quick Ratio
8.00

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.84 per share
Price / Book
1.51

Miscellaneous

Outstanding Shares
30,170,000
Free Float
26,101,000
Market Cap
$129.73 million
Optionable
Optionable
Beta
0.19

Social Links

A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Sergio Traversa M.B.A. (Age 64)
    Pharm.D., CEO & Director
    Comp: $1.79M
  • Mr. Maged S. Shenouda M.B.A. (Age 60)
    R.Ph., Chief Financial Officer
    Comp: $1.01M
  • Mr. Charles S. Ence CPA (Age 59)
    M.B.A., Chief Accounting & Compliance Officer
    Comp: $995.03k
  • Dr. Paolo Manfredi M.D. (Age 62)
    Ph.D., Chief Scientific Officer
  • Ms. Gina DiGuglielmo
    VP & Head of Clinical Operations
  • Dr. Marco Pappagallo M.D. (Age 65)
    Chief Clinical Officer
  • Mr. John Hixon
    Head of Commercial
  • Dr. Andrew Cutler
    Senior Clinical Development Advisor
  • Dr. Richard M. Mangano (Age 74)
    Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RLMD Stock Analysis - Frequently Asked Questions

What is Relmada Therapeutics' stock price target for 2024?

0 analysts have issued 1-year price targets for Relmada Therapeutics' stock. Their RLMD share price targets range from $25.00 to $25.00. On average, they anticipate the company's stock price to reach $25.00 in the next year. This suggests a possible upside of 525.0% from the stock's current price.
View analysts price targets for RLMD or view top-rated stocks among Wall Street analysts.

How have RLMD shares performed in 2024?

Relmada Therapeutics' stock was trading at $4.14 on January 1st, 2024. Since then, RLMD stock has decreased by 3.4% and is now trading at $4.00.
View the best growth stocks for 2024 here.

When is Relmada Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RLMD earnings forecast.

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics, Inc. (NASDAQ:RLMD) issued its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.88) by $0.04.

What ETF holds Relmada Therapeutics' stock?

AdvisorShares Psychedelics ETF holds 72,123 shares of RLMD stock, representing 4.53% of its portfolio.

How do I buy shares of Relmada Therapeutics?

Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RLMD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The #1 Crypto for 2024
InvestorPlace
Your Money is Not Safe
American Alternative